<DOC>
	<DOC>NCT01201720</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic patients with "acute-on-chronic liver failure".</brief_summary>
	<brief_title>Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"</brief_title>
	<detailed_description>The purpose of this study is to evaluate the effects on plasma exchange with 5% albumin on albumin functional capacity, cardiocirculatory, renal and cerebral function in cirrhotic patients with "acute-on-chronic liver failure", renal disfunction, cerebral disfunction ,and inflamtory response</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>Age between 18 and 80 years old Hepatic cirrhosis diagnosed by biopsy or clinical, analytic and ultra sound data. acute on chronic liver failure: defined by an acute deterioration in hepatic function produced in 24 weeks with jaundice (total serum bilirubin ≥ 5 mg/dl ) and hepatic encephalopathy (≥ grade 2) and/or renal insufficiency (serum creatinine ≥ 2 mg/dl) Neoplasm disease including hepatocarcinoma which exceed Milan criteria (1 tumour &gt; 5cm, up to 3 tumours &lt;3 cm) Active bacterial or fungal infection with hemodynamic instability which require the utilization of vasoactive drugs at moderate dose (&gt;0,5 μg/Kg/min of noradrenaline) Structural moderate to severe cardiopathy (Cardiac Index &lt;2l/min/m2) Chronic renal insufficiency in treatment with haemodialysis Chronic moderate o severe pulmonary disease (maximum expiratory volume in a second &lt;50%) Active transplant human immunodeficiency virus infection Pregnancy or lactation Acute respiratory distress syndrome (P02/Fi02&lt; 200mm Hg) or acute lung injury (P02/Fi02&lt; 300mm Hg) Hemodynamic instability (&gt;0,5 μg/Kg/min of noradrenaline) Bleeding in the digestive tract in the previous 72h to the treatment Severe coagulopathy: INR ≥ 3.0 (Quick ≤ 20%) and/or platelets &lt; 30000//mm3 Extrahepatic cholestasis Hepatobiliary surgery in the last 6 months (except laparoscopic Cholecystectomy) Concentrations bilirubin ≥ 5mg/dl during the period above 4 weeks previous to inclusion Concomitant participation in an other clinical trial Drug addiction Mental status which does not allow the patient to understand the trial, with the exception of hepatic encephalopathy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>cirrhosis</keyword>
	<keyword>cirrhotic patients with acute on chronic liver failure</keyword>
</DOC>